Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist. - Wikidata - wikimedia - TriplyDB

Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist.

Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist.

http://www.wikidata.org/entity/Q33942806

about

Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model Homotypic NK cell-to-cell communication controls cytokine responsiveness of innate immune NK cells Toll-like receptor 4 activation in cancer progression and therapy Immunotherapy using dendritic cells against multiple myeloma: how to improve?Cellular immunotherapy using dendritic cells against multiple myeloma Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity.Cellular uptake of exogenous calcineurin B is dependent on TLR4/MD2/CD14 complexes, and CnB is an endogenous ligand of TLR4.Optimal culture conditions for the generation of natural killer cell-induced dendritic cells for cancer immunotherapy.NK cells: key to success of DC-based cancer vaccines?Engineered dendritic cells for gastrointestinal tumor immunotherapy: opportunities in translational research.Anti-tumor Activity of Toll-Like Receptor 7 Agonists.siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo.Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model

P2860

Q27023621-D291AD10-D21C-4012-B0A9-4955B6365535 Q33689002-9D6353CD-3980-4102-852A-8D6A874B673D Q34635717-099B78F2-04A0-48E5-86BF-B9B2126141A1 Q35550677-82F7CAB2-DD8F-4C60-AA18-99387A397164 Q35852574-87F862D7-D15A-45D2-B6E6-14782CD22691 Q35865581-C05CCDE8-674E-49CB-BF5E-24DCE51D5FB0 Q36545286-B99B9EB4-034F-4E07-A762-0AD4544D608D Q36810015-17CBD498-A566-4507-BC1E-1F96D51E8086 Q37729135-7C4BD168-C080-4E10-90E3-8B77FFF66F8A Q38036202-269BB824-2245-4213-B659-F58256396267 Q38051671-9CED1294-6BBF-47AE-BC56-65DC4B9A996D Q39377049-303ADB8B-B99C-4D63-A8C3-8C83DAFA5817 Q39572943-07247246-8F5B-43DB-9103-11AA9A9B7E91 Q58801894-75CE15AB-4549-468E-A611-36FFC87776A9

P2860

Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist.

http://www.wikidata.org/entity/Q33942806

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Enhancement of antitumor effec ...... of Toll-like receptor agonist.

@ast

Enhancement of antitumor effec ...... of Toll-like receptor agonist.

@en

type

label

Enhancement of antitumor effec ...... of Toll-like receptor agonist.

@ast

Enhancement of antitumor effec ...... of Toll-like receptor agonist.

@en

prefLabel

Enhancement of antitumor effec ...... of Toll-like receptor agonist.

@ast

Enhancement of antitumor effec ...... of Toll-like receptor agonist.

@en

P1433

Q33942806-96F62394-8FA5-4A0B-9622-1FA8AA182159

P1476

Q33942806-2D6F6122-2113-4938-83F7-CE0CAEE83D18

P2093

Q33942806-0F7C14DD-D1DC-45D4-BA6C-88E90DC49559

Q33942806-199B316C-DE7D-45D0-A721-3EB92A0171E4

Q33942806-3621663F-ADFB-45AD-A205-623886F084DC

Q33942806-5F83727B-50BB-412C-B1EC-19D795288664

Q33942806-6EDDA3A5-C09F-4DAF-B365-B606E72CC499

Q33942806-712B1309-0953-4FDF-BFC4-58B4B22AEC4E

Q33942806-740F40C8-5D22-461D-AA20-B91586CF2BB5

Q33942806-977BC468-29C0-477D-A969-6892BEC29A39

Q33942806-C4B8016C-E937-4C96-AB6D-80E692F95877

Q33942806-D6549626-4835-4952-A49B-4CFE3D2B6CC0

P2860

Q33942806-07670492-CEB9-4672-BBE7-E455D7706A49

Q33942806-1044AB51-15E8-4607-AA5E-9C95146C29D9

Q33942806-166C7AF3-F46D-45DF-A03F-89EE28B1A02D

Q33942806-1B7472B3-1CF9-44CB-9A3C-CEB1040938B0

Q33942806-27F26233-C148-4742-8982-B97458E3B2B5

Q33942806-3BCD0F00-5187-4B2B-98F4-074C5EF957BC

Q33942806-507919DD-F7F6-4EC7-964E-30CB46EBFBF3

Q33942806-54F67FB8-26A3-4167-A950-0D7EF84A7CB0

Q33942806-55760D40-AA1E-45FA-AFD3-FE2790A57A32

Q33942806-6415C27E-AA3A-49A3-AA6E-C94AAF3C89AA

P2888

Q33942806-B467FEFA-64D2-4896-8374-40ADE771B87E

P304

Q33942806-65AED6E4-A068-4EDA-AE66-0D4BD971ACED

P31

Q33942806-0A24C9D8-A6BA-4063-90ED-6AB772F7BE95

P356

Q33942806-3321F432-759C-48CA-BA55-811182BD47BE

P433

Q33942806-D473211E-0A86-423A-933B-893E08A67388

P478

Q33942806-5AB61ADA-97F0-413A-8D1D-E04A77967433

P577

Q33942806-03E39D3E-F320-4F24-ACFB-B43A16EF125C

P5875

Q33942806-0DF8605D-9C57-443A-8092-8381E685F3D7

P6179

Q33942806-B6F3AD45-83C7-4221-B232-47774F10A09D

P698

Q33942806-0F289FC5-81C2-4C74-9AF9-D4FA9E57827E

P921

Q33942806-D2A6E711-4AA9-44B2-8FDC-222F7E233158

P932

Q33942806-6631524B-463D-4F56-AE29-F08572DA8245

P356

EMM.2010.42.6.042

P1433

Experimental and Molecular Medicine

P1476

Enhancement of antitumor effec ...... of Toll-like receptor agonist.

@en

P2093

Byoung Chul Park

http://www.w3.org/2001/XMLSchema#string

Cheol Yi Hong

http://www.w3.org/2001/XMLSchema#string

Deok-Hwan Yang

http://www.w3.org/2001/XMLSchema#string

Hyeong-Rok Kim

http://www.w3.org/2001/XMLSchema#string

Hyeoung-Joon Kim

http://www.w3.org/2001/XMLSchema#string

Ik-Joo Chung

http://www.w3.org/2001/XMLSchema#string

Je-Jung Lee

http://www.w3.org/2001/XMLSchema#string

Joon-Haeng Rhee

http://www.w3.org/2001/XMLSchema#string

Jung-Joon Min

http://www.w3.org/2001/XMLSchema#string

Thanh Nhan Nguyen Pham

http://www.w3.org/2001/XMLSchema#string

P2860

Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells

An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow

Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors.

In vivo cyclophosphamide and IL-2 treatment impedes self-antigen-induced effector CD4 cell tolerization: implications for adoptive immunotherapy.

A blast from the past: clearance of apoptotic cells regulates immune responses.

Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway

Natural killer cells and dendritic cells: rendezvous in abused tissues.

Recognition of pathogen-associated molecular patterns by TLR family.

Clinical applications of dendritic cell vaccination in the treatment of cancer.

NK cell and DC interactions.

P2888

emm.2010.42.6.042

P304

407-419

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3858/EMM.2010.42.6.042

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43131256

http://www.w3.org/2001/XMLSchema#string

P6179

1047506108

http://www.w3.org/2001/XMLSchema#string

P698

20386085

http://www.w3.org/2001/XMLSchema#string

P921

Toll-like receptor

P932

2892594

http://www.w3.org/2001/XMLSchema#string